AU · rank #18 · 2026-09-09
DSFIR
AMSTERDAM · EUR · $26.57B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.600 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.04 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 13 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $93.62 | +0.8% |
| Momentum acceleration 3-month minus 12-month momentum. | +25.24% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.05 |
| Gross margin TTM | +39.2% |
| 52w high | $96.74 |
| Market cap (USD) | $26.57B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
DSM-Firmenich is a €26.6B specialty ingredients company serving food, nutrition, health and beauty markets through three focused business units following its pending divestiture of Animal Nutrition & Health to CVC.
Rationale
100% analyst revision agreement across 19 analysts, a 75% upside-to-target, and 60–90-day EPS upgrades totaling ~€0.16 confirm broad, sustained fundamental re-rating momentum anchored by Q2 2026 EBITDA beat and management's guidance lift to the upper end of its growth range.
Material risks
- 1Vitamins and nutritional ingredient commoditization remains a live margin threat—if lower-cost rivals erode pricing in bulk nutrition, the 2026–2028 EBITDA margin staircase (19% → 22–23%) unravels and the re-rating thesis collapses.
- 2The 53% analyst target dispersion is unusually wide for a consensus-upgrade story, signaling deep disagreement on terminal value and synergy realization that could trigger sharp de-rating if the €500M synergy ambition slips.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.